We investigated the possibility of a direct action of androgens on the expression of the human corticotropin-releasing hormone (CRH), which plays a central role in the hypothalamicpituitary-adrenal (HPA)-axis. Colocalization of CRH and nuclear/cytoplasmic androgen receptor (AR) was found in neurons of the paraventricular nucleus (PVN) in the human hypothalamus. A potential androgen-responsive element (ARE) in the human CRH promoter was subsequently analyzed with bandshifts and cotransfections in neuroblastoma cells. In the presence of testosterone, recombinant human AR bound specifically to the CRH-ARE. Expression of AR in combination with testosterone repressed CRH promoter activity through the ARE. We conclude that androgens may directly affect CRH neurons in the human PVN via AR binding to the CRH-ARE, which may have consequences for sex-specific pathogenesis of mood disorders.
Introduction
Corticotropin-releasing hormone (CRH), a 41-aminoacid peptide, plays a crucial role in stress response and in the regulation of immune and inflammatory reactions. 1 The hypothalamic-pituitary-adrenal (HPA) axis is regarded by many as the final common pathway for a number of signs and symptoms of depression. 2, 3 CRH neurons in the hypothalamic paraventricular nucleus (PVN) are the central driving force for the HPA axis response to stress. 4 A number of studies have pointed to the presence of sex differences in the regulation of the stress response, in the prevalence of affective disorders, and to a sexual dimorphism of the immune and inflammatory reactions. [5] [6] [7] [8] [9] [10] [11] [12] It is suggested that gonadal steroids, for example, estrogens and androgens, are implicated in these sex differences and that they interact in a regulatory manner with substrates of the stress response, including the HPA axis. 13, 14 There is evidence that estrogens increase the HPA axis activity, enhance the HPA axis response to psychological stress, and sensitize the hypothalamicpituitary-ovarian axis to stress-induced inhibition. 15, 16 In rats, ovariectomy reduces basal and stress-induced levels of corticoid steroids, but these may be restored to normal by administration of estrogens. [17] [18] [19] In humans, CRH-stimulated adrenocorticotropic hormone (ACTH) release was moderately reduced in oral contraceptive users, 20 and an enhanced adrenocortical responsiveness to stress during the luteal phase of the cycle has been reported. 21 CRH and estrogen receptor-a were found to be colocalized in the PVN of the human hypothalamus, 22 whereas estrogen-responsive elements (EREs) were found in the CRH gene promoter region, which is good evidence for direct estrogenic regulation of human CRH gene expression. 23 On the other hand, various studies also implicate androgens in the regulation of mood. Males typically show reduced ACTH and corticosterone responses to stress as compared to females, an effect that is attributed in part to the inhibitory effects of testosterone on the HPA axis. [24] [25] [26] In controlled clinical studies, supraphysiological doses of androgens induce prominent mood changes in approximately 5% of eugonadal men, 27, 28 whereas in placebo-controlled clinical trials, physiological doses of testosterone produce antidepressant-like effects in hypogonadal men in some, 29, 30 but not all, 31 studies. Moreover, it was found that testosterone levels were lower in severely depressed male patients, 32 and older men with lower bioavailable testosterone levels were found to be more frequently depressed. 33 In addition, gonadectomized male rats show increased plasma ACTH and corticosterone responses to several forms of stress, which can be reversed with testosterone or dihydrotestosterone (DHT), the reduced nonaromatizable form of testosterone, indicating an androgen receptor (AR)-mediated effect. 34, 35 However, although it is well known that androgens, like estrogens, also act as signal transduction molecules, neurotrophic factors, and/or neuromodulators through their specific intracellular receptor 36, 37 and that androgen receptor immunoreactivity (AR-ir) is found in the human hypothalamus, including the human PVN, 38 the exact mechanisms through which androgens exert their effects on CRH neurons is not well understood. Here, we show that a subpopulation of neurons in the PVN express both CRH and the AR. Furthermore, we identify an androgen-responsive element (ARE) in the CRH gene promoter region, which initiates a repressing effect of AR on CRH expression.
Methods

Immunocytochemical study
Human brain material. The brains of 14 subjects (ten men and four women) ranging in age from 44 to 83 years were used for immunocytochemistry, and the brains of five subjects (three men and two women) ranging in age from 61 to 88 years were used for Western blots. They were all obtained at autopsy within the framework of the Netherlands Brain Bank (coordinator Dr R Ravid). Permission was obtained for a brain autopsy and for the use of the material and medical records for research purposes. The absence of neuropathological changes was confirmed by systematic neuropathological investigation 39 by a neuropathologist (Dr W Kamphorst, Free University Amsterdam).
Histology and immunocytochemistry. The hypothalami were dissected at autopsy and fixed in 0.1 M phosphate buffered 4% w/v formaldehyde (pH7.2) for 1-2 months. Tissues were dehydrated in graded ethanols, embedded in paraffin and serially cut in frontal sections (6 mm) on a Leitz microtome and stored at room temperature (RT). Every 100th section was stained with thionine (0.1% w/v thionine in acetate buffer, pH 4) in order to localize the PVN before immunocytochemical staining.
For ARIE antibody specificity tests, a slightly modified immunocytochemical protocol that was previously described in detail 38, 40 was used for AR staining. The main point of modification was omitting the step of signal amplification with biotinylated tyramine (1:1000) and 0.01% peroxide.
For the immunocytochemical study of the colocalization of CRH and AR, the monoclonal rat anti-CRH 'PFU 83' (IgG2a subclass) antibody (kindly provided by Professor FJH Tilders), aimed at the C-terminal part (amino acid 38-39) of rat/human CRH, [41] [42] [43] and a polyclonal rabbit anti-AR antibody, ARIE, raised in our institute against the first 20 amino acids of human AR peptide sequence of the N-terminus, coupled to thyroglobulin by glutaraldehyde, were used. Specificity of the antibody rat IgG, PFU83 had been confirmed previously, 41, 44 whereas the specificity of ARIE is described below. Double staining for AR and CRH was performed on a section at approximately the center of the complete PVN region for each subject. The sections were stretched and mounted on SuperFrost/Plus (Menzel, Germany) slides. Following deparaffinization and rehydration in graded ethanols, the sections were exposed to microwave oven pretreatment for antigen retrieval in 0.05 M Tris-HCl buffer (pH 7.6) at 901C for 30 min. Sections were then incubated overnight in 1% TBS (0.05 M Tris buffer pH 7.6 containing 0.15 M NaCl) -milk for 60 min to reduce nonspecific staining, and subsequently with anti-AR (ARIE/15.09.98) 1:1000 diluted in supermixmilk (0.25% gelatin, 0.5% Triton X-100 and 5% of milk powder in TBS, pH 7.6) at 41C. The next day the sections were rinsed in TBS for 3 Â 10 min and subsequently incubated with anti-rabbit IgG conjugated with alkaline phosphatase (Jackson ImmunoResearch Laboratories INC., West Grove, USA) 1:50 diluted in supermix-milk at RT for 1 h, then equilibrated in detection buffer (100 mM Tris-HCl, 100 mM NaCl, and 5 mM MgCl 2 , pH 9.5) for 5 min. Next, the sections reacted to 0.38 mg/ml nitroblue tetrazolium and 0.18 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP; Roche Molecular Biochemicals, Mannheim, Germany) in detection buffer for 20 min. Then 0.24 mg/ml levamisole was added to inhibit endogenous alkaline phosphatase activity. Nonspecific precipitate was removed by washing in 100% methanol for 10 min. Sections were rinsed for 3 Â 5 min and then incubated overnight with rat IgG, PFU83 (1:5000) diluted in supermix (0.25% gelatin, 0.5% Triton X-100 in TBS, pH 7.6) at 41C. The following day the sections were incubated with biotinylated anti-rat IgG (Vector) 1:200 in supermix at RT for 1 h, then incubated in ABC elite kit (1:400, Vector Labs, Burlingame, CA, USA) diluted in TBS for 1 h. Sections were then incubated with biotinylated tyramide diluted 1:750 in TBS plus 0.01% hydrogen peroxide (H 2 O 2 ) for 15 min to amplify the immunocytochemical reaction of the CRH antigen, 45 and incubated in ABC elite kit (1:400, Vector Labs, Burlingame, CA, USA) diluted in TBS again for 1 h. Subsequently, the sections were equilibrated in 0.2 M acetic-acid buffer (pH 5) for 5 min, followed by incubation with a filtered suspension of 5 mg of 3-amino-9-ethylcarbazole (AEC) in 10 ml 0.2 M acetic-acid buffer (pH 5) containing 0.5 ml N,Ndimethylformamide and 5 ml 30% hydrogen peroxide (H 2 O 2 ). The sections were then washed in TBS and coverslipped with Kaisers Glycerin gelatin (Merck, Darmstadt, Germany).
Western blot analysis for ARIE
The brains were obtained at autopsy according to the Netherlands Brain Bank protocol, dissected, quickly frozen in liquid nitrogen and subsequently stored at À801C. Sections of 50 mm were cut with a cryostat. From these samples protein was isolated according to the method described before by Kruijver et al. 46 Nuclear extracts (see below) or tissue supernatant were used for Western blotting according to the procedure described before by Kruijver et al., 46 with the following adjustments: as a washing buffer we used PBS-Tween (0.15 M NaCl, 9 mM Na 2 HPO 4 Á 2H 2 O, 1.7 mM NaH 2 PO 4 .H 2 O (pH 7.4), 0.1% and the blots were preincubated in PBS-Tween-milk (PBS-Tween, 5% milkpowder, Elk, Campina, The Netherlands) for 1 h at RT and subsequently incubated in anti-human androgen receptor antibody (ARIE) 1:1000 in PBS-Tween-milk for 1 h at RT, followed by an overnight incubation at 41C. The next day the protocol described by Kruijver et al. 46 was used again, with the following adjustments: blots were first rinsed twice in PBS-Tween-milk for 2 Â 15 min, and the substrate used was Western Lightning chemiluminescence reagent (PerkinElmer).
Photomicrographs
Photomicrographs were made with the help of an IBAS image-analysis system (Kontron Electronic, Munich, Germany).
Nuclear extracts and bandshift analysis
Oligonucleotides were labeled with gamma-32 P-ATP and gel purified as described previously. 47 After purification, the unlabeled antisense strand was annealed in twofold excess. Sequences were as follows (only upper strand is given): CRH-ARE: GGGGTTCAGGAACATTTTTTTCCTTACTCC; ARE-1: CTAGAAGTCTGGTACAGGGTGTTCTTTTTGCA; C3 gene ARE: AAGCTTAGTACGTGATGTTCTAAGCTT; MMTV-ARE: AAGCTTGTTACAAACTGTTCTAAGCTT; SV40-Sp1: AAATAGTCCCGCCCCTAACTCCGCCCAT.
Nuclear extracts were made 48 from 293T cells 49 transiently transfected with an expression plasmid for human AR (a kind gift of Dr J Trapman, Rotterdam, The Netherlands) or an empty expression plasmid (pcDNA3, Invitrogen). Cells were transfected for 16 h using calcium phosphate. 50 After transfection, testosterone was added to a final concentration of 25 mM for 24 h.
Nuclear extracts (5 mg) were incubated with 20 fmol of labeled oligonucleotide in 20 mM HEPES-KOH, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.1% NP-40, 15% glycerol, 2.5 mg/ml bovine serum albumin and 1 mg of poly (dIdC/dIdC) in a volume of 20 ml for 30 min before gel electrophoresis (4% polyacrylamide, 0.25 Â TBE, 2.5% glycerol) at 20 V/cm for 90 min. Gels were vacuum-dried and exposed to Biomax MS film (KODAK) for 4 days using an intensifying screen at À801C
Cell culture
The SK-N-BE(2)c neuroblastoma cell line expressing endogenous CRH mRNA 51 was a kind gift of Dr André BP van Kuilenburg (Academic Medical Center, University of Amsterdam, The Netherlands). The cells were cultured in high-glucose Dulbecco's Modified Eagle's Medium (Life Technologies, Grand Island, NY, USA), supplemented with 25 mM HEPES Buffer (Sigma-Aldrich, Germany), 10% v/v fetal calf serum (Life Technologies), 100 IU/ml penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technologies) at 371C in humidified air with 5% CO 2 . The cells were maintained in 75 cm 2 culture flasks (CellStar, Greiner Bio-One, Germany). SK-N-BE(2)c was used up to passage 26.
CRH luciferase plasmids
The human CRH promoter sequence from À2205 (pDFF145, containing the ARE) or À2145 (pDFF146, lacking the ARE) to þ 170 was amplified from HeLa cell genomic DNA with proof-reading DNA polymerase (Expand HiFi kit, Roche). The PCR products were cloned in the pGL3-Basic plasmid (Promega), and verified by sequencing.
Transfection
The SK-N-BE(2)c cells were seeded into six-well plates (CellStar, Greiner Bio-One, Germany) at a density of 0.5 Â 10 6 cells per well. One day after the seeding of the cells, they were transfected according to the calcium phosphate mediated transfection method 50 with 5 mg of CRH-luciferase plasmid and 1 mg of the AR expression plasmid per well.
At 24 h after transfection, 10 mM testosterone (Fluka, cat. 86500, Switzerland) in DMSO or DMSO was added to the wells.
Luciferase assays
Cells were harvested 48 h after transfection and lucifererase activity was measured by using the Luciferase Assay System (Promega, Madison, WI, USA). The total amount of proteins was determined according to the Bradford method. 52 Luciferase measurements were normalized for protein content.
Results
ARIE antibody specificity
The ARIE antibody readily recognized cells containing AR-ir in human tissues. Human hypothalamic mamillary body (MB) samples were stained with ARIE. They showed the characteristic pattern of localization of AR, similar to that described in previous reports on human tissues with the widely studied AR antibody PG21. 38, 40, 53, 54 AR-ir was seen both in the nucleus and/or in the cytoplasm of the cells in human MB (Figure 1a) , which was consistent with previous studies. 38, 40 No AR-ir was observed after omission of the primary antisera. Preadsorption of the primary antisera with the peptide antigen blocked all specific immunostaining in the human MB (Figure 1b) . Paraffin-embedded sections of formalin-fixed human testes showed a clear nuclear ARir with ARIE, both in peritubular cells and spermatocytes (Figure 2) , as also reported for PG21 earlier. 38 Moreover, MB sections of two male-to-female transsexual subjects (#88-064 and #98-137), which had been studied before with the antibody PG21 by our group, 40 were re-examined with the antibody ARIE. The researchers were blind to the identities of the studied subjects during the quantification, while the standards for the staining intensity scale were kept the same as for the earlier PG21 studies. Similar results were obtained with ARIE as obtained earlier with PG21 (data not shown). Lateral hypothalami from different patients were used for Western blots (see above). The ARIE antibody revealed a primary band located at the appropriate molecular weight of 110 kDa as described for human, 53, 54 whereas no band was present when the preimmune serum of the same rabbit was used ( Figure 3 ). Taken together, these data show that staining of AR with the antibody ARIE is specific.
Colocalization of CRH and AR in the human PVN All 14 subjects clearly revealed that about one-third of the CRH neurons colocalized AR in the hypothalamic PVN, that is, blue AR nuclear or cytoplasmic staining by alkaline phosphatase, red cytoplasmic CRH staining by peroxidase, and/or purple CRH-AR double staining cytoplasm (Figure 4 ). In addition, single AR nuclear and/or cytoplasmic staining was observed both inside ( Figure 4 , black arrow) and outside the PVN.
An ARE in the CRH promoter
The colocalization data strongly suggested that AR could be involved in the regulation of the human CRH gene. In order to determine whether AR could act on the CRH promoter by an ARE, the human CRH promoter region (GenBank accession number X67661) was searched for consensus ARE motifs. We used the consensus sequence determined by Roche et al. 55 and the fuzznuc program in the EMBOSS package. 56 At position À2160 of the human CRH gene, there is a sequence strongly resembling an ARE ( Figure 5) .
We performed bandshift analysis of this potential ARE in the CRH promoter, and of the high-affinity in vitro selected ARE (ARE-1). 55 In addition, oligonucleotides for two natural AREs, that is the MMTV-ARE 57 and the C3 gene ARE, 58 were used in order to further compare the binding affinity of the CRH-ARE with these natural AR-binding sites. An oligonucleotide containing the Sp1-binding site from SV40 served as a negative control. In the presence of testosterone, recombinant hAR bound strongly to the high-affinity oligonucleotide (ARE-1, indicated by an arrow in Figure 6 ), whereas a weak band with the same mobility was observed on the CRH-ARE oligonucleotide ( Figure 6 ). The complex on the ARE-1 site was specific, as it was competed away by an excess of unlabeled ARE-1, and by an excess of unlabeled CRH-ARE, and it reacted with antiserum (ARIE) against AR. A strong complex with higher mobility than AR is present on the CRH-ARE, which could compete for the binding of AR to this sequence. The fact that unlabeled CRH-ARE oligonucleotide could compete for binding of AR to the high-affinity ARE-1 oligonucleotide suggested that AR binds to the CRH-ARE with reduced affinity.
To compare the binding affinity of the CRH-ARE with those of natural AREs, hAR was titrated away from the high-affinity ARE-1 oligonucleotide in increasing concentrations of unlabeled oligonucleotides of MMTV or C3-gene ARE, whereas SV40-Sp1 served as a negative control. Significantly, the CRH-ARE has a lower affinity for the AR than the in vitro selected sequence, but its binding activity is very similar to that of known AREs from the MMTV 57 and C3 gene 58 ( Figure 7 ). These findings showed that the AR can bind to a sequence upstream of the transcriptional start site of the CRH gene, with an affinity comparable to that of other androgen-responsive genes.
AR represses the CRH promoter
We cotransfected CRH-promoter reporter constructs with AR expression plasmid in SK-N-BE(2)c neuroblastoma cells. A plasmid containing the CRH promoter sequence from À2205 to þ 170 (pDFF145) had a basal expression higher than a plasmid from À2145 to þ 170 (pDFF146), indicating that the region between À2205 and À2145 contains a positive promoter element (Figure 8 ). Cotransfection of hAR and an addition of testosterone one day before sampling repressed the longer construct, but did not affect the expression of the shorter one. Expression of hAR or testosterone addition alone did not significantly affect expression of pDFF145, indicating that hAR requires its ligand for this repressor activity (Figure 8 ). These findings suggest that hAR and an unknown positive-acting transcription factor compete for binding of the CRH promoter region between À2205 and À2145.
Discussion
The double-label immunocytochemistry and bandshift analysis experiment presented here show that the AR is colocalized with CRH in the human PVN, and that there is a specific ARE present in the human CRH promoter region. The potential ARE in the human CRH promoter has an AR-binding affinity similar to that of two well-characterized AREs: the Figure 6 Bandshift analysis of a high affinity ARE-1 (lanes 1-8) and the CRH-ARE (lanes 9-16). Nuclear extracts were isolated from mock-transfected 293T cells (lanes 1, 3, 9 and 11) or from hAR-transfected 293T cells (lanes 2, 4-8, 10 and 12-16) that were treated with testosterone (lanes 3-8 and 11-16) or with solvent (lanes 1, 2, 9 and 10). Competition was performed with 10 pmol (which was a 500-fold excess) double-stranded competitor in lanes 5, 6, 13 and 14, with ARE-1 competitor applied in lanes 5 and 13 while with CRH-ARE competitor in lanes 6 and 14. An a-specific antiserum (1 ml) was added in lanes 7 and 15, and 1 ml of AR specific antiserum, ARIE, was added in lanes 8 and 16. The arrow indicates the specific AR complex. . The AR-ARE-1 complex without competitor was used as a reference, and complex formation in the presence of competitor DNA was plotted against the ratio of labeled over cold oligonucleotide (in % labeled oligonucleotide). Logarithmic curve fitting was performed, the correlation coefficient (R) of the fit is indicated. Note that the relative affinity of AR for the CRH-ARE is similar to the affinity for the MMTV-and the C3-AR-binding sites.
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57,58 and the C3 gene ARE. 58 The cotransfection experiment revealed that AR together with testosterone can repress CRH promoter activity through this ARE between À2205 and À2145. The same promoter region also contains a positive-acting element, whose interacting transcription factor could be the high-mobility protein binding to the CRH-ARE ( Figure 6 ). These novel observations provide evidence that androgens are capable of influencing human CRH production directly, which is consistent with the finding that the nonaromatizable form of testosterone, DHT, can change the activity of the rat HPA axis via an AR-mediated effect. 34, 35 The HPA axis therefore seems to be a potential target, not only for estrogens but also for direct effects of androgens.
In contrast to our data, Bingaman et al. 59 did not find AR in rat hypothalamic CRH neurons. The discrepancy between the studies might be explained by a number of factors. Firstly, species differences may be involved. It is well known that in the rat, peptides like CRH can only be efficiently stained following colchicine injection into the ventricle before killing in order to inhibit axonal transport. 60, 61 This was not carried out by . In contrast to the rat, CRH in the human PVN neurons is readily stainable. Secondly, as shown by the present study AR inhibits CRH production. This means that CRH cells containing nuclear AR might express less CRH, making it even more difficult to detect colocalization of CRH and AR in the rat. Lastly, more sensitive immunocytochemical procedures were used in the present study, such as antigen retrieval (microwave) and amplification for reaction of the CRH antigen with biotinylated tyramide, as shown in the Methods section.
Circulating testosterone may act on nerve cells in different ways: it may act (1) through direct binding to AR, (2) after conversion to DHT through the 5-areductase pathway followed by binding to AR, (3) after conversion to estradiol through the aromatase pathway followed by binding to ER, or (4) it may be converted by one of the many metabolic pathways into an androgenic metabolite that binds to neither AR nor ER. 62 The highest levels of brain aromatase activity have been found in various limbic regions, such as the preoptic and other hypothalamic regions, which overlap extensively with brain regions containing estrogen receptors, [63] [64] [65] [66] whereas several studies have provided evidence for a direct effect of estrogens on the regulation of human CRH gene expression. 23 Our present study offers the first evidence of a direct effect of androgens on CRH neurons in the hypothalamus via AR. These findings are consistent with previous studies in rat that showed that androgens decrease the hypothalamic CRH content and CRH-IR cell numbers in the PVN. [24] [25] [26] Our data also agree with the opposing effects of androgens and estrogens on the rat pituitary-adrenal function. 15, 16 The new information of a direct effect of androgens on the regulation of CRH neurons may thus help to better understand the mechanism behind the sex differences in the regulation of stress response and the HPA axis. The balance between the androgen's direct and indirect activity, or, more specifically, the interplay between the ER and AR on the CRH gene promoter region, thus remains an interesting topic for further study.
The HPA axis, which is generally considered to be the 'final common pathway' in the stress response and in depressive symptomatology, 2,3 is highly susceptible to neonatal programming. [67] [68] [69] In rodents, early androgen exposure disrupts feminine behavior, gonadotropin release and neuroanatomical sexual differentiation 70, 71 and suppresses the HPA axis, 72 whereas in human, prenatal estrogen administration, that is, by DES, was found to increase the risk of affective disorders. 73, 74 These observations, together with our present data raise the possibility that androgens may also play a role, either via direct or indirect effects, in prenatal programming and in activity of the adult CRH neurons, and may thus be involved in the sex differences in the stress response and in the risk for mood disorders. 34, 75, 76 It was also of interest to find single AR nuclear and/ or cytoplasmic staining inside the PVN in the human hypothalamus ( Figure 4 ) as this implicates a potential role of androgens on the activity of peptidergic neurons other than CRH neurons, for example the vasopressin or oxytocin-containing neurons, both of which are also involved in central stress responses and mood disorders. [77] [78] [79] [80] [81] [82] This topic also deserves further study.
